Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Defronzo

Showing results (71-80 of 313) with videos related to

Pageof 32
Sort By:
Diabetes Care|May 20, 2008
One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetesMuhammad A Abdul-Ghani, Tamam Abdul-Ghani, Nibal Ali, et al.
The Journal of Clinical Endocrinology and Metabolism|February 22, 2019
Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant ParticipantsDevjit Tripathy, Aurora Merovci, Rita Basu, et al.
Diabetes Care|June 29, 2004
Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic populationEtta L Fanning, Beatrice J Selwyn, Anne C Larme, et al.
The Lancet. Diabetes & Endocrinology|September 19, 2018
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES)John P Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
The Journal of Clinical Endocrinology and Metabolism|June 18, 2014
The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazoneRalph A DeFronzo, Devjit Tripathy, Muhammad Abdul-Ghani, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetesMandeep Bajaj, Swangjit Suraamornkul, Sangeeta Kashyap, et al.
Expert Opinion on Pharmacotherapy|November 20, 2015
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitusC Triplitt, C Solis-Herrera, E Cersosimo, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 30, 2008
Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjectsYoshinori Miyazaki, Hiroshi Akasaka, Hirofumi Ohnishi, et al.
Diabetes Care|November 20, 2008
Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia StudyMuhammad A Abdul-Ghani, Valeriya Lyssenko, Tiinamaija Tuomi, et al.
Nutrients|May 14, 2013
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart diseaseMelania Gaggini, Mariangela Morelli, Emma Buzzigoli, et al.
Pageof 32

Showing results (71-80 of 313) with videos related to

Sort By:
Pageof 32
Diabetes Care|May 20, 2008
One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetesMuhammad A Abdul-Ghani, Tamam Abdul-Ghani, Nibal Ali, et al.
The Journal of Clinical Endocrinology and Metabolism|February 22, 2019
Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant ParticipantsDevjit Tripathy, Aurora Merovci, Rita Basu, et al.
Diabetes Care|June 29, 2004
Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic populationEtta L Fanning, Beatrice J Selwyn, Anne C Larme, et al.
The Lancet. Diabetes & Endocrinology|September 19, 2018
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES)John P Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
The Journal of Clinical Endocrinology and Metabolism|June 18, 2014
The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazoneRalph A DeFronzo, Devjit Tripathy, Muhammad Abdul-Ghani, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetesMandeep Bajaj, Swangjit Suraamornkul, Sangeeta Kashyap, et al.
Expert Opinion on Pharmacotherapy|November 20, 2015
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitusC Triplitt, C Solis-Herrera, E Cersosimo, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 30, 2008
Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjectsYoshinori Miyazaki, Hiroshi Akasaka, Hirofumi Ohnishi, et al.
Diabetes Care|November 20, 2008
Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia StudyMuhammad A Abdul-Ghani, Valeriya Lyssenko, Tiinamaija Tuomi, et al.
Nutrients|May 14, 2013
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart diseaseMelania Gaggini, Mariangela Morelli, Emma Buzzigoli, et al.
Pageof 32